Shionogi & Co., Ltd. · TSE:4507
Shionogi & — Shareholder Meeting (June 2021)
24 slides from Shionogi &'s shareholder meeting presentation, June 2021
Slide 1: The 156th Business Report
The 156th Business Report from April 1, 2020 to March 31, 2021.
Slide 2: Accounting Standard Comparison Table (JGAAP vs IFRS)
(Reference) Accounting Standard Comparison Table （ The main change is in the red ） JGAAP IFRS Consolidated Statement Consolidated Statement of Profit or Loss of Profit or Loss Sales Revenue Operating income Operating profit Ordinary income Profit before tax Profit attributable to owners Profit att
Slide 3: Current State of the Shionogi Group
Current State of the Shionogi Group 3
Slide 4: Vision 2030 and New Medium-Term Business Plan STS2030
Vision 2030 and New Medium-Term Business Plan “STS2030“ Vision 2030 Strategy to achieve 2030 Vision Building Innovation Platforms to Shape the Future of Healthcare STS2030 - Shionogi Transformation Strategy 2030 - STS2030 STS Phase1 (’20-’24) STS Phase2 (’25-) 4
Slide 5: Three strategies for STS Phase1
New Medium-Term Business Plan “STS2030“ Three strategies for STS Phase1 New value creation i. R&D strategy Development of innovative pipeline ii. Top-Line Business growth through creation of Strategy diverse businesses Infrastructure iii. Management building Foundation Building framework for new val
Slide 6: Business Operations and Results
Business Operations and Results 6
Slide 7: Financial Results (Consolidated) – Revenue and Each profit
① Financial Results (Consolidated) – Revenue and Each profit - • Sales and profits decreased due to shrinking of the pharmaceutical market by COVID-19 • Aggressive investment in R&D and new businesses by redirecting sales activity costs Summary of consolidated statement of income for FY2020 （B yen）
Slide 8: Financial Results (Consolidated) – Assets, etc.
① Financial Results (Consolidated) – Assets, etc. - • Maintain a stable financial base • Progress in efforts to improve corporate value over the medium to long term Items of consolidated statement of financial position （B yen） Y on Y Change FY2019 FY2020 (%） Total assets 873.7 999.0 14.3% Total equi
Slide 9: Royalties and Dividend Income From ViiV
② Royalties and Dividend Income From ViiV Royalties and dividend income from the HIV franchise stably increased 193.2B yen 168.0B yen △13.1% (vs prior FY) ■ Royalty income from others and transient milestones (including income from Roche) 154.5B yen 146.7B yen ■ Royalty income and dividend income fr
Slide 10: Domestic Business
③ Domestic Business • Sales of infectious disease drugs including the influenza family decreased due to the impact of the novelcoronavirus （Down 39.1% YonY） • Increase in sales of Cymbalta and Intuniv 52.9 B yen 49.3B yen Significant shrinkage of the market for （△6.8% vs prior FY） community-acquir
Slide 11: Overseas Business - Maximize the value of Cefiderocol
③ Overseas Business - Maximize the value of Cefiderocol (Fetroja/Fetcroja)* - • Increase in sales of Fetroja in US • Building a new infectious disease business model in EU US：Increase in sales of Fetroja EU：selected as part of a subscription reimbursement model 0.05 B yen 1.7 B yen （Up 3,508.8% Yo
Slide 12: Overseas Business – China Business
③ Overseas Business – China Business - • Good progress towards business transformation by Ping An-Shionogi • Start selling products via online healthcare platform Selling products via online Acceleration of AI drug discovery healthcare platform Analyzing a large amount of integrated data at high s
Slide 13: R&D – core 8 Projects
④ R&D - core 8 Projects - Steady progress of core 8 projects Solid tumor Non-clinical studies are progressing to Regulatory Epidermolysis bullosa support initiation of Phase I study in T cell FY2021 Preparations for submission (Japan) inhibitor redasemtide Ischemic stroke Psycho-neurological disease
Slide 14: Manufacture and supply chain
⑤ Manufacture and supply chain • Shionogi Pharma：establish a growth foundation as a CDMO* • Continue stable supply of medicines without causing shortages even in the pandemic by COVID-19 * CDMO : Contract Development Manufacturing Organization Evolution of manufacturing by Responsibility for stabl
Slide 15: Challenges Ahead
for youl_/) Challenges Ahead @® SHIONOGI
Slide 16: Issues to be addressed and a review of the current fiscal year
Issues to be addressed and a review of the current fiscal year Challenges to be addressed for sustainable growth Results for the current period Progress in R&D Advancement of of growth drivers core 8 projects Strengthening domestic Creation of business Growth of Actions for total and overseas busine
Slide 17: Current Issues and What Shionogi Wants to Achieve
Current Issues and What Shionogi Wants to Achieve Providing solutions for the overwhelmed medical system Safe and effective Prevention Diagnosis Treatment treatments Epidemic Asymptomatic person forecasting Vaccination Lumira ** Recuperation at home Small-molecule Rapid, easy and therapeutics Sewage
Slide 18: Initiatives for COVID-19 in FY2021 - Vaccines
Initiatives for COVID-19 in FY2021 - Vaccines - R&D of Genetic recombinantprotein vaccine For the introduction of purely domestic vaccines • Conducting Ph1/2 trials in Japan • Preparing for Ph3 trials to start by end of year Started discussion on alternative methods to evaluate efficacy and safety
Slide 19: Initiatives for COVID-19 in FY2021 - Therapeutic drugs
Initiatives for COVID-19 in FY2021 - Therapeutic drugs - R&D of therapeutic drugs For development of therapeutic drugs with superior efficacy and safety • Accelerate R&D of promising oral compounds from small molecule drug discovery • Preparing for the start of clinical trials during the first half
Slide 20: As a Company Needed by Society
As a Company Needed by Society － Shionogi‘s commitment in FY2021 － As a leading company in the infectious disease field Shionogi will work intensively to counter the COVID-19 pandemic as our highest priority 20
Slide 21: Dividend Policy
for youl_/) Dividend Policy @® SHIONOGI
Slide 22: Shareholder return policy
Shareholder return policy through which shareholders can feel our growth Plan to increase dividend for （円） the ninth consecutive year 150 108 110 （planned） （planned） 103 100 94 82 72 62 55 46 52 50 53 50 42 38 44 （planned） 28 34 20 22 24 0 FY 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 Buyback
Slide 23: Building Innovation Platforms to Shape the Future of Healthcare
2030 Vision - What we want to achieve by 2030 - Building Innovation Platforms to Shape the Future of Healthcare 23
Slide 24: Forward-Looking Statements
Forward-Looking Statements Forecast or target figures in this material are neither official forecasts of earnings and dividends nor guarantee of target, achievement and forecasts, but present the midterm strategies, goals and visions. Official earnings guidance should be referred to in the disclos